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plasma folate (8.9±3.8 to 34.3±16.5µg/l & 9.9±4.1 to 17.4±7.6µg/l respectively; ∆ high c.f.
low dose p<0.001). Both doses of folic acid significantly (p<0.001) lowered plasma total
homocysteine (12.9±5.6 to 9.9±2.6µmol/l for high dose & 11.7±3.1 to 10.5±1.8µmol/l for
low dose; ∆ high c.f. low dose p=0.219). However, FMD was improved only following high
(99±35 c.f. 24±26µm pretreatment, p<0.001) and not low (42±32 c.f. 26±59µm pretreat-
ment, p=0.264) dose folic acid. No differences between groups were evident for any of
the other parameters measured.
Conclusion: The data demonstrate that high but not low dose folic acid improves endot-
helial function in CAD despite a significant reduction in homocysteine in both treatment
groups. This suggests that the beneficial effects of folic acid on endothelial function occur
via a mechanism that is independent of homocysteine-lowering. These results have
important implications for the current clinical trials of folic acid supplementation using low
dose folic acid.
1159-187 Long-Term Use of Pioglitazone Slows Arteriosclerotic 
Progression in Type 2 Diabetics
Tatsuaki Murakami, Masateru Ohnaka, Fukui Cardiovascular Center, Fukui, Japan
Introduction and hypothesis: Insulin resistance is thought to be highly involved in arte-
riosclerotic processes, but the long-term effects of insulin sensitizing agents remain
unknown. We assessed hypothesis that long-term use of pioglitazone, an insulin sensi-
tizer, slows ultrasonic manifestation of atherosclerosis.
Methods: Thirty type-2 diabetic patients with suspected coronary artery disease were
randomized to group-P where they received pioglitazone (30mg per day) for more than 1
year, or to group-C where they continued therapy without thiazolidinedione for more than
1 year. We noninvasively ultrasonic quantified flow mediated dilation of brachial artery
after 5 minutes forearm occlusion (FMD) and we also quantified arterial stiffness by bra-
chial-to-ankle pulse wave velocity (PWV). Changes in FMD and PWV from the baseline
through the follow-up point were compared between the 2 groups. Results: Group-P
(n=15) manifested good compliance to the treatment and improvements in insulin resis-
tant variables represented by HOMA-IR while group-C showed no improvement. FMD
was improved after medication in group-P (p<0.01) but not in group-C (p=ns). PWV
decreased in group-P (p=0.02) but increased in group-C (p=0.03). 
Conclusion: In conclusion long-term pioglitazone use improves endothelial function and
arterial wall compliance, which may have beneficial potentials for management of arterio-
sclerosis in type-2 diabetics.
1159-188 Grape Seed and Skin Extracts Alter Platelet Function 
and Release of Reactive Oxygen Species
Olga Vitseva, Sonia Varghese, Subrata Chakrabati, John Folts, Jane E. Freedman, 
Boston University School of Medicine, Boston, MA
Background: Moderate red wine consumption is inversely associated with coronary
ischemia. Red wine and purple grape juice (PGJ) contain polymeric flavonoids with anti-
oxidant properties believed to be protective against cardiovascular events. Acute cardiac
events are also associated with decreased platelet-derived nitric oxide (NO) release. In
this study, the effects of extracts from grape skins or seeds on platelet function, NO, and
superoxide release were determined.
Methods and Results: Incubation of platelets with seed (100 mg/L) or skin (250 mg/L)
extract led a decrease in platelet aggregation of 65% ± 7% and 49% ± 9%, respectively
(n=6; P<0.001). Grape seed or skin extract increased platelet-derived NO release by
126% ± 19% and 92% ± 20%, respectively (n=5, P<0.001). Platelet incubation with
extracts led to a marked decrease in superoxide release from 73 ± 6 to 2 ± 3 for grape
seeds and to 7.3 ± 6.4 for grape skin (arb. Chemilum. units; n=5, P<0.0001). These
effects were dose-dependent for both grape extracts. Coincubation with seeds and skins
led to additive effect on inhibition of platelet aggregation, enhanced NO release, and
ablated superoxide production, but did not significantly alter release of aggregation
induced soluble CD40 ligand, a marker of inflammatory-thrombotic interactions.
Conclusion: The skins and seeds from grapes inhibit platelet function and increase bio-
active NO. These effects may be due to the markedly decreased release of superoxide
anion or via another antioxidant-sparing mechanism. Red wine has been shown to
enhance vascular function via a NO-dependent mechanism and the extracts derived from
grapes appear to provide similar beneficial properties.
1159-189 Echocardiographic Correlates of Pulmonary 
Hypertension in 2,337 Patients
James N. Mohn, Richard W. Asinger, Charles A. Herzog, Bradley A. Bart, Hennepin 
County Medical Center, Minneapolis, MN
Background: Echocardiographic findings in a large population of unselected patients
with pulmonary hypertension (PH) have not been reported, and are herein described.
Methods: Using our echocardiographic database, we retrospectively identified all adult
patients having measurable tricuspid regurgitation (n=14,869). Patients with estimated
RV-RA gradients _ 40 mmHg were defined as having PH (n=2,337); those having gradi-
ents _ 20 were defined as having no PH (n=3,136). Demographic information, clinical
data and codified echocardiographic findings were analyzed for their association with PH.
Differences between cohorts were assessed using the t-test and chi square test for con-
tinuous and dichotomous variables, respectively.
Results: The PH cohort was significantly older (64.3±16.9 yrs vs. 47.1 ± 17.7 yrs) and
had a small but significant male preponderance (50.3% vs. 45.2%). Body mass index
(BMI) was significantly greater in the PH group (30.2 ± 10.2 vs. 27.3± 7.3), and grouped
analyses of echocardiographic parameters are presented below.
Conclusion: PH was present in over 15% of patients with measurable tricuspid regurgi-
tation. Compared to patients without PH, there are striking differences in age, sex, weight
and measures of atrial, LV, RV and valvular morphology and function. A significant num-
ber of PH patients (25.3%) lacked left-sided pathology that could contribute to the pres-
ence of PH. To our knowledge, this study represents the largest cohort of unselected PH
patients described. 
1159-190 Role of the 807 C/T Polymorphism of Glycoprotein Ia/IIa 
on Platelet Function Following Clopidogrel Loading 
Dose in Patients Undergoing Coronary Stenting
Dominick J. Angiolillo, Antonio Fernández-Ortiz, Esther Bernardo, Celia Ramirez, 
Elisabetta Trabetti, Chiara Stranieri, Manel Sabate, Fernando Alfonso, Pierfranco 
Pignatti, Carlos Macaya, San Carlos University Hospital, Madrid, Spain, Univeristy of 
Verona, Verona, Italy
Background: The 807 C/T polymorphism of the glycoprotein (GP) Ia/IIa is the major
platelet-collagen receptor. In particular, T allele carriers have increased receptor density
and thrombotic risk. Aim of the study was to assess the role of the 807 C/T polymorphism
on platelet aggregation (PA) following a 300 mg clopidogrel loading dose (LD) after coro-
nary stenting (CS). Methods: The 807 C/T genotype was assessed in 44 patients (P). P
were divided into 2 groups: carriers (CT + TT genotypes) and non-carriers (CC genotype)
of the T allele. All P were on aspirin and those receiving GP IIb/IIIa blockers were not
included. PA (expressed as %) was assessed at baseline (B), and 4hrs and 24hrs follow-
ing LD by light transmittance aggregometry using ADP (6 µM) and collagen (6 µg/mL) as
agonists. Results: There were 32/44 T allele carriers and 12/44 CC homozygotes. ADP-
induced PA did not differ between groups (Table). Following collagen stimuli, PA was
higher (*p<0.05) in T allele carries following LD (Table). PA reduced (#p<0.001) at 4 and
24 hrs in all P except after collagen stimuli in T allele carriers. There were no differences
in fibrinogen and von Willebrand factor levels, platelet count, and clinical status. Conclu-
sions: The T allele of the GP Ia/IIa gene is associated with increased platelet reactivity
and a lower response to clopidogrel LD following collagen stimuli. This suggests that T
allele carriers have a more extensive platelet adherence to fibrillar collagens which may
contribute to their increased thrombotic risk.
1159-191 Effect of a Single High-Fat Meal on Endothelial 
Microparticles as a Marker of Endothelial Injury
Arley A. Peter, Alexandre Ferreira, Salim Virani, Eduardo de Marchena, Santiago Garcia, 
Reyan Ghany, Josh Purow, Joaquim Jimenez, Yeon Ahn, Jackson Memorial Hospital 
University of Miami, Miami, FL
BACKGROUND: This study was designed to evaluate a possible relationship between
levels of CD31+/CD42b- Endothelial Microparticles (EMP), markers of endothelial injury,
and cholesterol levels in healthy volunteers.
METHODS: A total of 23 healthy subjects without any major risk factors or previous car-
diovascular risk factors were evaluated. A fasting cholesterol profile and EMP levels were
measured in all subjects. Endothelial microparticles were measured by flow cytometry
using fluorescent monoclonal antibodies.
RESULTS: Subjects were divided in two different groups according to fasting total cho-
lesterol. Group A had cholesterol levels below 200 mg/dl (157 + 31) and group B had
serum cholesterol equal or greater than 200 mg/dl ( 258.4 + 11.14); p: < 0.0001. The
measured levels of EMP (x10^6/mL) were 0.388824 + 0.053954 in group A and 0.964 +
0.185148589 in group B (P< 0.0001). The 17 subjects in group A were then fed a high fat
meal containing 900calories, 50g of fat, 14g of saturated fat, and 255mg of cholesterol.
The measured levels of EMP (x10^6/mL) fasting, at one hour and three hours were
0.388824 + 0.053954, 0.541176 +0.138649 and 0.676667 +0.158505, respectively.
Baseline
group-P
Follow-up
group-P
Baseline
group-C
Follow-up
group-C
FMD 4.1±1.6% 7.1±2.7% 1727±269cm/s 1664±234cm/s
PWV 4.1±1.8% 4.2±1.7% 1710±232cm/s 1797±215cm/s
Clinical and Echocardiographic 
Findings
Pulmonary 
Hypertension
(n=2,337)
No Pulmonary 
Hypertension
(n=3,136)
p-value
Age in years (mean ± SD) 64.3 ± 16.9 47.1 ± 17.7 <.001
Gender Female (%) 49.7% 54.8% <.001
BMI (Kg/m2 , mean ± SD) 30.2 ± 10.2 27.3 ± 7.3 <.001
Abnormal LV Morphology or Function 69.4% 30.6% <.001
Abnormal RV Morphology or Function 35.9% 11.3% <.001
Abnormal Atrial Morphology or Rhythm 58.0% 23.3% <.001
Moderate or Severe Left Sided Valvular 
Disease
35.0% 7.8% <.001
Pericardial Abnormalities 20.5% 9.5% <.001
Any L-Sided Abnormalities (Valvular, 
Structural or Functional)
74.7% 41.0% <.001
ADP B 4 hrs 24 hrs
CC 61±16 43±13# 32±9#
CT+TT 55±18 42±18# 35±19#
Collagen B 4 hrs 24 hrs
CC 42±15 30±13# 31±14#
CT+TT 47±19 43±21* 46±26*
